ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS

被引：0
|
作者：
Janjigian, Y. Y. [1 ]
Smit, E. F. [2 ]
Horn, L. [3 ]
Groen, H. J. M. [4 ]
Camidge, D. R. [5 ]
Gettinger, S. [6 ]
Fu, Y. [7 ]
Denis, L. J. [8 ]
Miller, V. [9 ]
Pao, W. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands
[3] Vanderbilt Univ, Nashville, TN USA
[4] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
[6] Yale Univ, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Pharmaceut Inc, Clin Trial Management, Ridgefield, CT 06877 USA
[8] Boehringer Ingelheim KG, Clin Dev & Med Affairs, D-6507 Ingelheim, Germany
[9] Fdn Med, Clin Dev, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：401 / 401
页数：1
相关论文
共 50 条
  • [1] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [2] AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS
    Cappuzzo, Federico
    Tiseo, Marcello
    Chiari, Rita
    Landi, Lorenza
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Facchi-Netti, Francesco
    Levra, Matteo Giaj
    Vari, Sabrina
    Crino, Lucio
    De Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S610 - S610
  • [3] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Rachiglio, Anna Maria
    Fenizia, Francesca
    Piccirillo, Maria Carmela
    Galetta, Domenico
    Crino, Lucio
    Vincenzi, Bruno
    Barletta, Emiddio
    Pinto, Carmine
    Ferrau, Francesco
    Lambiase, Matilde
    Montanino, Agnese
    Roma, Cristin
    Ludovini, Vienna
    Montagna, Elisabetta Sara
    De Luca, Antonella
    Rocco, Gaetano
    Botti, Gerardo
    Perrone, Francesco
    Morabito, Alessandro
    Normanno, Nicola
    [J]. CANCERS, 2019, 11 (03):
  • [4] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Montanino, A.
    Rocco, G.
    Galetta, D.
    Montagna, S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, M. C.
    Perrone, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
    Normanno, N.
    Rachiglio, A. M.
    Lambiase, M.
    Fenizia, F.
    Iannaccone, A.
    Chicchinelli, N.
    Morabito, A.
    Rocco, G.
    Galetta, D.
    Montagna, E. S.
    Crino, L.
    Ludovini, V.
    Vincenzi, B.
    Barletta, E.
    Pinto, C.
    Ferrau, F.
    Botti, G.
    Piccirillo, C.
    Perrone, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
    Elamin, Y.
    Robichaux, J.
    Carter, B.
    Altan, M.
    Gibbons, D.
    Fossella, F.
    Simon, G.
    Lam, V.
    Blumenschein, G., Jr.
    Tsao, A.
    Kurie, J.
    Mott, F.
    Negrao, M.
    Hu, L.
    He, J.
    Nilsson, M.
    Roeck, B.
    Yang, Z.
    Papadimitrakopoulou, V.
    Heymach, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S282 - S283
  • [7] Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
    Arcila, M. E.
    Riely, G. J.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    Pao, W.
    Miller, V. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Acquired Resistance to Afatinib in EGFR- Mutant Lung Cancer
    Sequist, L. V.
    Gerber, D. E.
    Fidias, P.
    Shaw, A. T.
    Temel, J. S.
    Heist, R. S.
    Gainor, J. F.
    Fulton, L.
    Kennedy, E. A.
    Muzikansky, A.
    Engelma, J. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S44
  • [9] Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Eric
    Melchior, Linea C.
    Urbanska, Edyta M.
    Jakobsen, Jan N.
    de Stricker, Karin
    Grauslund, Morten
    Sorensen, Jens B.
    [J]. CANCERS, 2019, 11 (07)
  • [10] A Phase lb Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI
    Park, Ji Soo
    Kim, Hye Ryun
    Hong, Min Hee
    Cho, Byoung Chul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1069 - S1070
12345